Skip to main content Skip to main navigation menu Skip to site footer

Microvessel density as predictor chemotherapy in locally advanced colorectal cancer

  • Maria Yustina ,
  • Tomy Lesmana ,
  • Alphania Rahniayu ,
  • Edwin Danardono ,
  • Denny Septarendra ,


Introduction: Colorectal cancer is the leading cause of morbidity and mortality worldwide. The role of neo-adjuvant chemotherapy in the treatment of locally advanced colorectal cancer (LACRC) has been increased the overall survival. We must consider the benefit and disadvantage of neoadjuvant therapy for LACRC, otherwise window for surgery diminish in progressive disease.  The growth of the tumor requires neoangiogenesis, and more aggressive the cancer, more active the angiogenesis. Micro Vessel Density (MVD) is the result of angiogenesis. In our simple thought, the tumor with rich vascular has better chemotherapy response due to enhance chemotherapy drug’s delivery. But the preclinical and clinical studies report that vascularity of the tumor is unlike normal tissue, tumor vascular is leaky and tortous, hence the interstitial fluid pressure increase, resulted in ineficiency of chemotherapy and oxygen delivery. This study aims to determine whether MVD beneficial as predictor of chemotherapy response in LACRC.

Methods: Fifty-one patients underwent colonoscopy biopsy and diagnosed with LACRC. The patient underwent abdominal CT scan for staging. They were treated with neoadjuvant FOLFOX (leucovorin, fluorouracil, oxaliplatin) and then underwent abdominal CT scan for evaluation chemotherapy response. The response of chemotherapy assessment based on RECIST criteria which classified into progressive disease, stable disease, partial response and complete response. MVD was examined using endothelial marker CD31 from the paraffin block from biopsy colonoscopy specimen 

Results: A total of 51 patients enrolled in the study, 27 (52.9%) responded to chemotherapy. The chemotherapeutic response was partial response in patients with well-differentiated pathological grade, but not statistically significant (n =20 (39.3%), p-value = 0.556, p >0.05). The MVD CD31 ranges between 7 – 82, the mean is 31.04, low MVD is identified in 25 patients and high MVD is identified in 26 patients. In this study, no significant correlation was recorded between gender, staging TNM, histologic grading, location of lesion and accuracy of chemotherapy and response of chemotherapy, the p-value is 0.809, 0.156, 0.298, 0.556, 0.573, and 0.259 respectively.  There is no statistically significant correlation between MVD and response to chemotherapy (OR: 0.92; CI 95%: 0.30-2.79; p = 0.991)

Conclusion: Pre-treatment CD31 micro-vessel density could not be used to predict neoadjuvant chemotherapy response in LACRC.


  1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019/01/06. 2019;14(2):89–103. Available from:
  2. Klaver CEL, Gietelink L, Bemelman WA, Wouters MWJM, Wiggers T, Tollenaar RAEM, et al. Locally Advanced Colon Cancer: Evaluation of Current Clinical Practice and Treatment Outcomes at the Population Level. J Natl Compr Cancer Netw. 2017;15(2):181–90. Available from:
  3. Izbicki JR, Hosch SB, Knoefel WT, Passlick B, Bloechle C, Broelsch CE. Extended resections are beneficial for patients with locally advanced colorectal cancer. Dis Colon & Rectum. 1995;38(12):1251–6. Available from:
  4. Cuccurullo V, Mansi L. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (7th edition). Eur J Nucl Med Mol Imaging. 2010;38(2):408. Available from:
  5. Li Y, Zhao L, Güngör C, Tan F, Zhou Z, Li C, et al. The main contributor to the upswing of survival in locally advanced colorectal cancer: an analysis of the SEER database. Therap Adv Gastroenterol. 2019;12:1756284819862154–1756284819862154. Available from:
  6. Ceniceros L, Pastor C, Sanchez-Justicia C, Arean C, Baixauli J, Chopitea A, et al. Neoadjuvant chemotherapy for locally advanced colon cancer patients: Long-term results from a single institutional experience. J Clin Oncol. 2021;39(15_suppl):e15598–e15598. Available from:
  7. Stojadinovic A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, et al. Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study. Ann Surg Oncol. 2012;19(13):4178–85. Available from:
  8. Group FC. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012/09/25. 2012;13(11):1152–60. Available from:
  9. Arredondo J, Baixauli J, Pastor C, Chopitea A, Sola JJ, González I, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol. 2016;19(3):379–85. Available from:
  10. den Uil SH, van den Broek E, Coupé VMH, Vellinga TT, Delis-van Diemen PM, Bril H, et al. Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study. BMC Gastroenterol. 2019;19(1):146. Available from:
  11. Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, et al. Tumor Neovascularization and Developments in Therapeutics. Cancers (Basel). 2019;11(3):316. Available from:
  12. Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, et al. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst. 2015;107(5):djv040. Available from:
  13. McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014/03/13. 2014;106(4):dju036–dju036. Available from:
  14. Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013/10/28. 2013;110(46):18632–7. Available from:
  15. Gabbani M, Giorgi C, Napoli G, Tebano U, Perrone MS, Missiroli S, Berretta M, Mandarà M, Zaninelli M, Luca N, Grigolato D, Muraro M, Rinaldi G, Pinton P, Fiorica F. Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment: A Meta-Anaysis of Randomized Controlled Trials. Clin Colorectal Cancer. 2022;21(4):297-308. Available from: doi: 10.1016/j.clcc.2022.07.005
  16. Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, et al. Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer. 2002;86(12):1905–8. Available from:
  17. Boonya-Ussadorn C, Nimmanon T, Anannamcharoen S. Pretreatment Microvessel Density for Predicting of Tumor Responsiveness to Neoadjuvant Chemoradiotherapy of Locally Advanced Rectal Cancer. Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2697-2703. Available from: doi: 10.31557/APJCP.2023.24.8.2697.
  18. Li W, Liang C, Liu P, Qi Y, Shen H, Li M, et al. Predictive value of microvessel features for the clinical response to neoadjuvant chemotherapy in cervical squamous carcinoma and the associations with prognosis. Transl Cancer Res. 2021;10(1):162–73. Available from:
  19. Dewhirst MW, Ashcraft KA. Implications of Increase in Vascular Permeability in Tumors by VEGF: A Commentary on the Pioneering Work of Harold Dvorak. Cancer Res. 2016;76(11):3118–20. Available from:
  20. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95(12):1683–8. Available from:
  21. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004;17(2):197–203. Available from:

How to Cite

Yustina, M., Lesmana, T. ., Rahniayu, A. ., Danardono, E. ., & Septarendra, D. . (2021). Microvessel density as predictor chemotherapy in locally advanced colorectal cancer. Bali Medical Journal, 13(1), 542–547.




Search Panel